Prominent Scientist to Lead Intrexon’s Clinical Research and Development
Dr. Sunil Chada joins Intrexon as Senior Vice President and will head company’s clinical trials
August 25, 2008
Intrexon, a developer of biotherapeutic control systems to enhance the safety and efficacy of existing and novel biological therapeutics, today announced the appointment of Sunil Chada, Ph.D as the Senior Vice President of Clinical Research and Development and an Officer of the Company. Dr. Chada will report directly to Intrexon’s Chief Executive Officer, Robert Beech and will be responsible for all aspects of the Company’s pre-clinical and clinical development programs.
“The addition of Dr. Chada further strengthens our efforts to improve patient outcomes by delivering novel, controllable therapeutics for critical disease areas,” said Robert Beech, Chief Executive Officer of Intrexon. “Dr. Chada‘s extensive preclinical and clinical research experience will play a vital role in the continued success and expansion of our clinical product development activities as we move current programs forward and launch new technology initiatives.”
Dr. Chada’s biotechnology experience spans more than two decades. He was most recently VP, Research and Development with Introgen Research Institute and Associate VP, Clinical Research and Development for Introgen Therapeutics Incorporated where he managed clinical trials in melanoma, lung, breast, and other cancers. During his tenure, he was responsible for developing programs from early stage research into clinical trials and he led the team which discovered predictive biomarkers to identify drug-responsive patients. His work has resulted in over 100 published scientific articles and more than 30 issued patents and patent applications. Dr. Chada was an adjunct faculty member at University of Texas M. D. Anderson Cancer Center and has served on advisory boards for the National Cancer Institute, Rice University, private philanthropic organizations and the Cancer Institutes of the Dutch and Italian governments. He has been awarded multiple grants for cancer research.
About Intrexon Corporation
Intrexon Corporation is a privately held life sciences company focused on the research and development of biotherapeutic control systems that help reduce toxicity while enhancing clinical outcomes. The company’s technology employs special genetic components and activator compounds to tightly control the delivery, targeting, activation, regulation and location of biologics. The company is headquartered at the Virginia Tech Corporate Research Center in Blacksburg, Virginia, with additional R&D operations in Valley Forge, Pennsylvania. More information is available at www.DNA.com.
Contact:
Linda Mecimore
Intrexon Corporation
Phone: 540-961-0725
E-mail: lmecimore@intrexon.com
Return to In the News